| Autor: |
Pollak, Michael, Costantino, Joseph, Polychronakos, Constantin, Blauer, Sue-Ann, Guyda, Harvey, Redmond, Carol, Fisher, Bernard, Margolese, Richard |
| Zdroj: |
JNCI: Journal of the National Cancer Institute; 11/3/1990, Vol. 82 Issue 21, p1693-1697, 5p |
| Abstrakt: |
Insulinlike growth factor I (IGF-I) has been shown to be a potent mitogen for breast cancer cells in vitro, and IGF-I receptors have been demonstrated on human primary breast neoplasms.In arandomized, placebo-controlled study, we document that administration of the antiestrogen tamoxifen to patients with breast cancer was associated with a statistically significant ( =.002) reduction in the serum level of IGF-I. The mean IGF-I level was 1.4 U/mL in the placebo-treated group and 0.9 U/mL in the tamoxifen-treated group. Because serum IGF-I level is growth hormone (GH) dependent and because data suggest that the pubertal surge in GH and IGF-I levels is sex steroid dependent, we sepeculate that the mechanism underlying our observation may involve blockade by tamoxifen of estrogen action in the hypothalamic-pituitary axis. We conclude that tamoxifen treatment reduces IGF-I levels and that this reduction may contribute to the therapeutic effect of the drug. [J Natl Cancer Inst 82:1693–1697,1990) [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
